vs

Side-by-side financial comparison of ASSEMBLY BIOSCIENCES, INC. (ASMB) and CuriosityStream Inc. (CURI). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $10.8M, roughly 1.8× ASSEMBLY BIOSCIENCES, INC.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -85.2%, a 65.5% gap on every dollar of revenue. On growth, ASSEMBLY BIOSCIENCES, INC. posted the faster year-over-year revenue change (57.6% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-15.2M).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

ASMB vs CURI — Head-to-Head

Bigger by revenue
CURI
CURI
1.8× larger
CURI
$19.2M
$10.8M
ASMB
Growing faster (revenue YoY)
ASMB
ASMB
+21.8% gap
ASMB
57.6%
35.8%
CURI
Higher net margin
CURI
CURI
65.5% more per $
CURI
-19.7%
-85.2%
ASMB
More free cash flow
CURI
CURI
$19.1M more FCF
CURI
$3.9M
$-15.2M
ASMB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASMB
ASMB
CURI
CURI
Revenue
$10.8M
$19.2M
Net Profit
$-9.2M
$-3.8M
Gross Margin
Operating Margin
-100.9%
-17.6%
Net Margin
-85.2%
-19.7%
Revenue YoY
57.6%
35.8%
Net Profit YoY
4.3%
-34.6%
EPS (diluted)
$-0.72
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASMB
ASMB
CURI
CURI
Q4 25
$19.2M
Q3 25
$10.8M
$18.4M
Q2 25
$9.6M
$19.0M
Q1 25
$9.4M
$15.1M
Q4 24
$7.4M
$14.1M
Q3 24
$6.8M
$12.6M
Q2 24
$8.5M
$12.4M
Q1 24
$5.8M
$12.0M
Net Profit
ASMB
ASMB
CURI
CURI
Q4 25
$-3.8M
Q3 25
$-9.2M
$-3.7M
Q2 25
$-10.2M
$784.0K
Q1 25
$-8.8M
$319.0K
Q4 24
$-2.8M
Q3 24
$-9.6M
$-3.1M
Q2 24
$-11.2M
$-2.0M
Q1 24
$-9.1M
$-5.0M
Operating Margin
ASMB
ASMB
CURI
CURI
Q4 25
-17.6%
Q3 25
-100.9%
-24.5%
Q2 25
-115.2%
2.5%
Q1 25
-105.5%
0.5%
Q4 24
-27.4%
Q3 24
-160.1%
-25.8%
Q2 24
-143.0%
-20.6%
Q1 24
-185.5%
-30.4%
Net Margin
ASMB
ASMB
CURI
CURI
Q4 25
-19.7%
Q3 25
-85.2%
-20.4%
Q2 25
-105.9%
4.1%
Q1 25
-93.6%
2.1%
Q4 24
-19.9%
Q3 24
-140.4%
-24.3%
Q2 24
-130.7%
-16.4%
Q1 24
-156.9%
-42.0%
EPS (diluted)
ASMB
ASMB
CURI
CURI
Q4 25
$-0.07
Q3 25
$-0.72
$-0.06
Q2 25
$-1.33
$0.01
Q1 25
$-1.17
$0.01
Q4 24
$-0.05
Q3 24
$-1.51
$-0.06
Q2 24
$-1.98
$-0.04
Q1 24
$-1.66
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASMB
ASMB
CURI
CURI
Cash + ST InvestmentsLiquidity on hand
$22.5M
$27.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$182.7M
$41.5M
Total Assets
$240.0M
$75.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASMB
ASMB
CURI
CURI
Q4 25
$27.3M
Q3 25
$22.5M
$27.8M
Q2 25
$24.0M
$28.1M
Q1 25
$23.4M
$33.4M
Q4 24
$38.3M
$32.1M
Q3 24
$28.5M
$33.2M
Q2 24
$19.2M
$39.5M
Q1 24
$18.7M
$38.8M
Stockholders' Equity
ASMB
ASMB
CURI
CURI
Q4 25
$41.5M
Q3 25
$182.7M
$47.2M
Q2 25
$18.1M
$49.8M
Q1 25
$27.1M
$58.1M
Q4 24
$33.4M
$57.8M
Q3 24
$26.0M
$62.2M
Q2 24
$34.7M
$64.8M
Q1 24
$32.6M
$67.0M
Total Assets
ASMB
ASMB
CURI
CURI
Q4 25
$75.7M
Q3 25
$240.0M
$74.7M
Q2 25
$80.8M
$78.7M
Q1 25
$99.0M
$85.3M
Q4 24
$119.2M
$86.2M
Q3 24
$100.3M
$87.6M
Q2 24
$115.3M
$90.9M
Q1 24
$119.9M
$94.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASMB
ASMB
CURI
CURI
Operating Cash FlowLast quarter
$-15.1M
$4.0M
Free Cash FlowOCF − Capex
$-15.2M
$3.9M
FCF MarginFCF / Revenue
-140.7%
20.5%
Capex IntensityCapex / Revenue
0.4%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASMB
ASMB
CURI
CURI
Q4 25
$4.0M
Q3 25
$-15.1M
$4.4M
Q2 25
$-16.8M
$2.8M
Q1 25
$-23.4M
$1.9M
Q4 24
$-51.1M
$3.0M
Q3 24
$-15.2M
$2.3M
Q2 24
$-17.1M
$2.2M
Q1 24
$-18.4M
$666.0K
Free Cash Flow
ASMB
ASMB
CURI
CURI
Q4 25
$3.9M
Q3 25
$-15.2M
Q2 25
Q1 25
$1.8M
Q4 24
$-51.1M
Q3 24
Q2 24
$-17.1M
Q1 24
$-18.4M
FCF Margin
ASMB
ASMB
CURI
CURI
Q4 25
20.5%
Q3 25
-140.7%
Q2 25
Q1 25
12.2%
Q4 24
-695.2%
Q3 24
Q2 24
-200.6%
Q1 24
-317.7%
Capex Intensity
ASMB
ASMB
CURI
CURI
Q4 25
0.1%
Q3 25
0.4%
0.0%
Q2 25
0.0%
0.0%
Q1 25
0.0%
0.5%
Q4 24
0.4%
0.0%
Q3 24
0.0%
0.0%
Q2 24
0.2%
0.0%
Q1 24
0.2%
0.0%
Cash Conversion
ASMB
ASMB
CURI
CURI
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons